Can Chinese Cosmetics Test Reports Be Used in Brazil?

Quick overview

Source review: October 19, 2026 · For: Brands and manufacturers with Chinese safety, quality, stability or efficacy studies preparing a Brazil launch.

A Chinese laboratory's SPF, microbiology or performance report may be an important asset for a Brazilian cosmetics dossier. The useful question is not simply where the document was issued. It is whether the study demonstrates the relevant property of the exact product intended for Brazil, under the required method and proposed Portuguese claim. Nor does an ISO/IEC 17025 certificate, by itself, guarantee acceptance of every test.

Start by separating four types of evidence

• Evidence type: Product safety / What it can support: Safety of the identified formula under its intended use / Common gap: Formula identity or special user groups are not covered
• Evidence type: Quality and microbiology / What it can support: Specifications, stability and microbial quality controls / Common gap: Missing batch, method or packaging context
• Evidence type: Claims and efficacy / What it can support: A specific moisturizing, SPF or repellency claim / Common gap: Study endpoint does not support the actual wording
• Evidence type: Category-specific registration tests / What it can support: A required technical point for a regulated product group / Common gap: Generic report substituted for a dedicated method

ANVISA publishes general safety-assessment, stability and quality-control guidance and has published a sunscreen regularization manual. These materials help plan evidence, but they do not show that a Chinese report will be automatically accepted or universally rejected. The sunscreen manual still cites several rules that have since been replaced, so use it only for limited technical topics; whether a report must be submitted, which method applies and what laboratory conditions are required must be checked against the current product category and petition. [BR-S02][BR-S09][BR-S10][BR-S11][BR-S15][BR-S18][BR-S19]

1. Do ordinary cosmetics always require a new human efficacy trial?

There is no useful one-size-fits-all testing matrix for every claim. Depending on the claim, suitable evidence may include controlled product testing, instrumental observations, consumer research or relevant scientific documentation. What matters is the strength of the claim, the identity of the tested finished product and the conditions under which the results apply.

“Helps skin feel moisturized” and “clinically proven to improve a defined skin parameter” make materially different claims. Start with a Claim Matrix listing Chinese, English and final Portuguese copy side by side, the evidence linked to each statement, formula version, study endpoint and remaining gap. This is a recommended internal tool, not a universal ANVISA form.

Ingredient-level literature should not be stretched into a finished-product efficacy promise when the study did not examine the product being marketed.

2. Why sunscreen reports require special attention

ANVISA currently lists sunscreens, including children's sunscreens, among cosmetics requiring registration. This is a product-path requirement, not a decision accepting any particular foreign laboratory report. [BR-S01]

ANVISA's 2024 sunscreen regularization manual covers evidence topics such as SPF, UVA and water resistance, but some underlying legal references have since been superseded. Use it to identify technical review topics, not as a substitute for current sunscreen requirements, the petition checklist or applicable methods. [BR-S10][BR-S02]

ANVISA's 2022 regulatory-consolidation notice places IN 121/2022 under saneantes (sanitizing and cleaning products), where it addresses acceptance criteria for test reports in that category. It cannot be generalized into automatic recognition of foreign reports for ordinary cosmetics. Existing Chinese reports can inform dossier preparation and evidence gap assessment; use as support for a specific ANVISA petition requires case-by-case confirmation. [BR-S20]

For an SPF report produced in China, check the actual method, reference conditions, study population or experimental system as applicable, sample identity, batch, technical result, label value and any additional UVA or other sunscreen claims. An SPF number on a cover sheet does not show that the complete Brazilian registration package is satisfactory.

Insect repellents, hair-straightening products and other special categories require their own rule and petition review; do not recycle a sunscreen testing plan for all of them. [BR-S01]

3. Must the laboratory be in Brazil or part of REBLAS?

The reviewed ANVISA materials do not establish one rule requiring every cosmetic efficacy study to be performed by a Brazilian or REBLAS laboratory. They also do not establish that any overseas laboratory report will be accepted. This question must not be reduced to a universal marketing promise.

For a publishable project decision, first check whether the specific category, official method or petition item imposes requirements on where or by whom the study must be performed. If the relevant official material is unclear, ask the Brazilian responsible filing party to confirm the current requirements or seek clarification from ANVISA. Do not claim an exemption that has not been established for the actual product.

Review competence at the level of the specific test, not only the institution: personnel, facilities, quality systems, appropriate method, validation and accredited scope where relevant. ISO/IEC 17025 can be useful evidence of laboratory competence, but certification should not be treated as unconditional approval of a particular cosmetic claim.

4. A five-part assessment of reports already produced in China

• Sample identity: Can the product code, formula version, concentration, dosage form, batch and packaging be traced to the Brazil-bound SKU?
• Evidence purpose: Is the report for safety, stability, microbial quality or a particular claim—and does the report actually establish that point?
• Method: Is the method appropriate to the applicable Brazilian product-specific technical requirement, especially for sunscreen claims?
• Laboratory capability: Is the laboratory competent for the stated method, and is a complete authenticated report available?
• Documentation: Are study design, conditions, results, relevant statistics, conclusions and any necessary translation or method explanation complete?

A helpful gap-review output distinguishes potentially reusable evidence, documentation needed, additional study needed, retest needed and confirmation required from the Brazilian filing party or authority. Avoid a simplistic report-level “accepted/not accepted” label without context.

5. Two practical scenarios

Scenario A: A face cream has Chinese stability and microbiology reports. If the reports identify the finished formula and appropriate conditions, they may help support the Brazil technical file. That does not automatically validate the formula, labeling and claims, nor does it settle every additional study question.

Scenario B: An imported sunscreen has a Chinese SPF report. First compare its method, sample and formula version, SPF/UVA results and proposed Portuguese claims, then have the responsible Brazilian filing party confirm the current petition. Missing method or version coverage may call for supplementary evidence or retesting; the report's country of origin does not decide acceptance, and the historical sunscreen manual does not replace the current checklist. [BR-S01][BR-S10]

These are assessment examples, not ANVISA decisions on real products.

6. Before commissioning a new Brazilian study

• Confirm the product's notification or registration route.
• Freeze the intended formula and sample identity.
• Collect the planned Portuguese claims and their original-language variants.
• Review existing reports, methods and laboratory scopes.
• Read product-specific technical rules before purchasing a test package.
• Document exactly why any supplementary study is needed.
• Have the responsible Brazilian filing party confirm the final submission checklist.

Frequently asked questions

Do Chinese reports require Portuguese translation? The required form depends on the actual petition and local documentation requirements. A complete and accurate translation may help a review, but do not presume one universal legalization or translation rule for all reports.

Does ISO/IEC 17025 mean ANVISA must accept a report? No such guarantee follows from the certificate alone. The scope, method, sample and product-specific requirements still matter.

Can we assess existing evidence before selecting an importer? Yes. A preliminary review can identify likely gaps without representing that ANVISA has already accepted the materials.